Tong-Xie-Yao-Fang strengthens intestinal feedback control of bile acid synthesis to ameliorate irritable bowel syndrome by enhancing bile salt hydrolase-expressing microbiota

• Published in: Journal of ethnopharmacology 2024-09, Vol.331, p.118256-118256, Article 118256
• Main Authors: Jia, Fengjing, Du, Liqing, He, Jinchao, Zhang, Zhaozhou, Hou, Xinxin, Dong, Qinjun, Bian, Zhaoxiang, Zhao, Ling
• Format: Article
• Language: English
• Subjects: Amidohydrolases - metabolism; Animals; Bile acids; Bile Acids and Salts - metabolism; Chronic stress; Disease Models, Animal; Drugs, Chinese Herbal - pharmacology; Gastrointestinal Microbiome - drug effects; Gut microbiota; Herbal formula; Irritable bowel syndrome; Irritable Bowel Syndrome - drug therapy; Irritable Bowel Syndrome - metabolism; Irritable Bowel Syndrome - microbiology; Male; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled - metabolism; Visceral hyperalgesia
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2024.118256

A herbal formula Tong-Xie-Yao-Fang (TXYF) is traditionally used to treat irritable bowel syndrome (IBS), modern pharmacological evidence supports that the formula efficacy is associated with altered gut microbiota. Yet, the mechanistic role of gut microbiota in the therapy of TXYF remains unclear. We previously clarified that gut microbiota-dysregulated bile acid (BA) metabolism contribute to the pathogenesis of IBS, deriving a hypothesis that microbiota-BA metabolic axis might be a potential target of TXYF. We aim to investigate a new gut microbiota-mediated mechanism underlying anti-IBS efficacy of TXYF. We established an IBS rat model with a combination of stressors, compared the herbal efficacy in models undergone gut bacterial manipulations, also examined BA metabolism-related microbiota, metabolites, genes and proteins by 16S rRNA gene sequencing, targeted metabolomics, qPCR and multiplex immunofluorescence staining. We observed that TXYF attenuated visceral hyperalgesia and diarrhea in IBS rats but not in those underwent gut bacteria depletion. Transferring gut microbiota from TXYF-treated donors also decreased visceral sensitivity and slightly relief diarrhea-like behaviors in IBS recipient rats. Fecal 16S rRNA gene sequencing revealed that TXYF modulated microbial β-diversity and taxonomic structure of IBS rats, with a significant increase in relative abundance of bile salt hydrolase (BSH)-expressing Bacteroidaceae. qPCR and culturing data validated that TXYF had a promotive effect on the growth and BSH activity of Bacteroides species. TXYF-reshaped microbiota upregulated the expression of intestinal Fgf15, a feedback signal to control BA synthesis in the liver. As a result, the BA synthetic and excretory levels in IBS rats were decreased by TXYF, so as that colonic BA membrane receptor Tgr5 sensing and its mediated Calcitonin gene-related peptide (Cgrp)-positive neuronal response were attenuated. This study poses a new microbiota-driven therapeutic action for TXYF, highlighting the potential of developing new anti-IBS strategies from the herbal formula targeting BSH-expressing gut bacteria. [Display omitted] •Gut microbiota mediates the efficacy of TXYF in IBS rats.•TXYF enhances the growth and metabolic activity of bile salt hydrolase-expressing bacteria.•TXYF-modified microbiota strengthens intestinal feedback control of bile acid synthesis.•TXYF-modified microbiota weakens rat colonic bile acid/Tgr5 sensing and Cgrp level.